Vitalli Bio ends Daewoong deal, Alector receives $50M Hercules Capital loan, Bavarian Nordic gets $340M vaccine orders, Nuvectis Pharma reports disappointing trial data, Flashpoint partners with Saudi ...
Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...
ALX Oncology has found a new chief medical officer, tapping Alan Sandler for the role. Sandler comes to ALX from Mirati, ...
Adaptimmune is slashing its headcount as part of a broader company restructuring aimed at saving $300 million ...
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Merz Therapeutics landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was ...
More cuts are hitting Gilead’s cell therapy wing, including the closure of a Philadelphia office. A small number of ...
The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending ...
Sen. Bill Cassidy (R-LA) will take over the Senate Health, Education, Labor, and Pensions Committee when the GOP gets control ...
The European Commission is seeking feedback from industry players about Novo Holdings' $16.5 billion proposed acquisition of ...
New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.
Novo Nordisk said Thursday that it plans to eventually halt all of its human insulin pen production globally, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback